The CCNG2 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the human CCNG2 gene. This population provides a loss-of-function model in HAP1 cells, enabling the study of CCNG2-dependent processes. As a polyclonal pool, it comprises a diverse set of edited alleles, reflecting a population-level knockout phenotype suitable for functional genomics and drug discovery research. The product serves as a versatile tool for investigating cyclin G2 biology without the limitations of single-cell clonal expansion.
The HAP1 host cell line is a near-haploid, adherent fibroblast-like cell line derived from the KBM-7 chronic myeloid leukemia line, originally isolated from a male patient. Its near-haploid karyotype simplifies genetic manipulation and analysis, making it a powerful tool for functional genomics and drug-target validation. HAP1 cells retain key features of hematopoietic malignancy, offering a physiologically relevant platform for studying leukemia-associated genes. Their adherent growth and fibroblastoid morphology permit standard cell culture and imaging protocols, enhancing experimental versatility.
CCNG2 encodes an atypical cyclin that operates as a negative regulator of cell cycle progression and pro-apoptotic factor. Transcriptionally activated by TP53, CCNG2 is also modulated by upstream regulators including FOXO3, TGF-??, and microRNAs miR-23a and miR-27a. At the protein level, CCNG2 binds the catalytic subunit PPP2CA and regulatory subunit PPP2R1A of protein phosphatase 2A (PP2A), directing dephosphorylation of key substrates such as AKT1 and MDM2. This activity suppresses AKT-mediated survival signaling and stabilizes p53 by counteracting MDM2, thereby reinforcing growth arrest and apoptosis. Downstream of CCNG2, diminished CDK2 activity and reduced Cyclin D1 (CCND1) expression further inhibit cell cycle machinery. Consequently, loss of CCNG2 disrupts these tumor-suppressive networks, potentially accelerating oncogenesis.
Within the HAP1 leukemic context, CCNG2 knockout allows dissection of the p53?CCCNG2?CPP2A?CAKT/MDM2 axis in a simplified genetic background. The near-haploid nature minimizes confounding allelic complexity, enabling clearer interpretation of gene-dosage effects and signaling perturbations. This model is particularly suited to investigating how CCNG2 loss influences chemotherapy sensitivity, since p53 status is a critical determinant of drug response in myeloid leukemias. Moreover, HAP1 cells express functional p53, permitting direct assessment of p53-dependent cyclin G2 functions without artificial p53 reconstitution.
Researchers can employ this polyclonal knockout population to study p53-mediated tumor suppression using p53 luciferase reporter assays, quantify CCNG2 expression via RT-qPCR and Western blotting, and analyze cell cycle distributions by flow cytometry. Apoptosis induction can be measured with Annexin V staining, while PP2A binding interactions are assessable through co-immunoprecipitation. Cell proliferation changes are monitored via MTS assays. The model also supports chemical biology screens for drug sensitivities and resistance in thyroid, breast, colorectal, prostate cancers, and leukemia. For further information, contact Ascent Research.
